Publication
New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis
Related publications (34)
Lansoprazole is an antituberculous prodrug targeting cytochrome bc1
Stewart Cole, Florence Pojer, Claudia Sala, Andrej Benjak, Anthony Vocat, Philippe Busso, Jan Lars Rybniker
Better antibiotics capable of killing multi-drug-resistant Mycobacterium tuberculosis are urgently needed. Despite extensive drug discovery efforts, only a few promising candidates are on the horizon and alternative screening protocols are required. Here, ...
Nature Publishing Group2015Whole cell screen based identification of spiropiperidines with potent antitubercular properties
Whole cell based screens to identify hits against Mycobacterium tuberculosis (Mtb), carried out under replicating and non-replicating (NRP) conditions, resulted in the identification of multiple, novel but structurally related spiropiperidines with potent ...
Elsevier2015Whole Genome Sequencing: Revolutionary Medicine or Privacy Nightmare?
Jean-Pierre Hubaux, Erman Ayday
Whole genome sequencing will soon become affordable for many individuals, but thorny privacy and ethical issues could jeopardize its popularity and thwart the large-scale adoption of genomics in healthcare and slow potential medical advances. ...
Ieee Computer Soc2015Multiscattering-enhanced optical probes for biosensing
Although reactive oxygen species (ROS) are an inescapable part of every living organism, we are only beginning to understand their functions and mechanics. As of now, we know that ROS are involved in cell signalling, stress-response and defence against pat ...
EPFL20154-Aminoquinolone Piperidine Amides: Noncovalent Inhibitors of DprE1 with Long Residence Time and Potent Antimycobacterial Activity
John McKinney, Neeraj Dhar, Joao Pedro De Almeida Neres, François Signorino-Gelo
4-Aminoquinolone piperidine amides (AQs) were identified as a novel scaffold starting from a whole cell screen, with potent cidality on Mycobacterium tuberculosis (Mtb). Evaluation of the minimum inhibitory concentrations, followed by whole genome sequenci ...
Amer Chemical Soc2014Tuberculosis drug discovery in the post-post-genomic era
Stewart Cole, Jan Lars Rybniker, Benoit Lechartier
The expectation that genomics would result in new therapeutic interventions for infectious diseases remains unfulfilled. In the post-genomic era, the decade immediately following the availability of the genome sequence of Mycobacterium tuberculosis, tuberc ...
Wiley Open Access2014The cysteine desulfurase IscS of Mycobacterium tuberculosis is involved in iron sulfur cluster biogenesis and oxidative stress defence
Stewart Cole, Florence Pojer, Gaëlle Séraphine Kolly, Jan Lars Rybniker, Jeffrey Chen
The complex multiprotein systems for the assembly of protein-bound iron sulfur (Fe S) clusters are well defined in Gram-negative model organisms. However, little is known about Fe S cluster biogenesis in other bacterial species. The ISC (iron sulfur cluste ...
Portland Press2014Towards a new tuberculosis drug: pyridomycin - nature's isoniazid
Stewart Cole, Florence Pojer, Claudia Sala, Ruben Hartkoorn, Joao Pedro De Almeida Neres, Swapna Uplekar, Raju Mukherjee, Sophie Magnet
Tuberculosis, a global threat to public health, is becoming untreatable due to widespread drug resistance to frontline drugs such as the InhA-inhibitor isoniazid. Historically, by inhibiting highly vulnerable targets, natural products have been an importan ...
Wiley Open Access2012Genomics and transcriptomics of the Mycobacterium tuberculosis complex
The goal of eliminating tuberculosis (TB) by 2050 depends on the development of improved TB diagnostics, drugs and vaccines. Advances in these areas require a deep understanding of the disease and its causative agent, Mycobacterium tuberculosis (M. tb). My ...
EPFL2012Identification and characterization of proteins supporting dehalorespiration in Desulfitobacterium hafniense strain TCE1
Respiration is a fundamental catalytic process in the aerobic and anaerobic energy metabolism of many prokaryotic and most eukaryotic organisms. The major difference between these organisms is that various organic and inorganic substrates can be used to do ...
EPFL2009